Related Experiment Videos
Hepatitis B vaccine in the expanded programme of immunisation: The Gambian experience. The Gambia Hepatitis Study
Insights
Hepatitis B vaccination integrated into The Gambia's national immunization program proved effective. This strategy successfully reduced persistent hepatitis B infections in children, demonstrating feasibility and efficacy in Africa.
Area of Science:
- Public Health
- Vaccinology
- Hepatology
Background:
- Hepatitis B infection poses a significant public health challenge, particularly in endemic regions.
- Integrating hepatitis B vaccination into existing national immunization programs is crucial for disease control.
Purpose of the Study:
- To assess the effectiveness of integrating the hepatitis B vaccine into the national Expanded Programme of Immunisation (EPI) in The Gambia.
- To evaluate the impact of this integration strategy on the prevalence of persistent hepatitis B infection in children.
Main Methods:
- The study involved integrating the hepatitis B vaccine into the national EPI without altering the existing immunization schedule or delivery mechanism.
- Serological results were analyzed from a sample of vaccinated children at one year of age.
Main Results:
- The integration strategy was effective in reducing the prevalence of persistently infected children.
- The vaccine demonstrated a low non-response rate (less than 2%).
- Antibody concentrations in responding children indicate adequate protection against high-risk persistent hepatitis B infection.
Conclusions:
- Integrating hepatitis B vaccine into national Expanded Programme of Immunisation (EPI) is a feasible and effective strategy in Africa.
- This approach successfully reduces the burden of persistent hepatitis B infection in children.
- The study supports the widespread adoption of hepatitis B vaccination within African EPIs.
Abstract:
As part of the Gambia Hepatitis Intervention Study, hepatitis B vaccine has been integrated into the national Expanded Programme of Immunisation (EPI) without major changes to the schedule of immunisation or to the mechanism of delivery. Serological results on a sample of vaccinated children at one year of age show that the strategy has been effective in reducing the prevalence of persistently infected children. The number of non-responders to the vaccine is low (less than 2%) and the antibody concentrations attained in responding children should give adequate protection when they are at high risk of persistent hepatitis B infection. Integration of hepatitis B vaccine into the EPI is feasible and effective in Africa.